Combining SGN-35 with Chemotherapy for Hodgkin Lymphoma
Author Information
Author(s): Oflazoglu Ezogelin, Kissler Kim M, Sievers Eric L, Grewal Iqbal S, Gerber Hans-Peter
Primary Institution: Seattle Genetics Inc.
Hypothesis
Does the combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improve antitumour activity in Hodgkin lymphoma?
Conclusion
The study found that combining SGN-35 with chemotherapy significantly improves antitumour responses in Hodgkin lymphoma without increasing toxicity.
Supporting Evidence
- Combining SGN-35 with ABVD resulted in 9/9 durable tumour regressions in all experimental animals.
- The combination of SGN-35 with gemcitabine enhanced antitumour activity and induced durable responses in all animals.
- Statistical analysis showed significant increases in tumour growth delay for combination treatments compared to individual treatments.
Takeaway
This study shows that using a special cancer drug together with regular chemotherapy can help fight a type of blood cancer called Hodgkin lymphoma better than using either one alone.
Methodology
The study used preclinical models of Hodgkin lymphoma in SCID mice to test the effects of SGN-35 combined with various chemotherapy regimens.
Potential Biases
All authors are employees of Seattle Genetics, which may introduce bias in the study's design and reporting.
Limitations
The study was conducted in preclinical models, and further clinical trials are needed to confirm the findings in humans.
Participant Demographics
The study involved SCID mice implanted with L540cy Hodgkin lymphoma cells.
Statistical Information
P-Value
P < 0.0001
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website